Supplemental Material 1. Comparison of final and excluded samples

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variable** | | **Final sample** | | **Excluded sample** | |
| **n** | **%** | **n** | **%** |
| Age | |  |  |  |  |
|  | 18–44 years | 465 | 86.9 | 1,087 | 87.5 |
|  | 45 years or older | 70 | 13.1 | 155 | 12.5 |
| Sex | |  |  |  |  |
|  | Male | 382 | 71.4 | 884 | 71.4 |
|  | Female | 153 | 28.6 | 355 | 28.7 |
| CD4 count at ART initiation | | |  |  |  |
|  | ≤200 cells/μL | 359 | 67.1 | 455 | 78.5 |
|  | >200 cells/μL | 176 | 32.9 | 125 | 21.6 |
| WHO clinical stage | |  |  |  |  |
|  | Stage 1 | 61 | 11.4 | 168 | 13.8 |
|  | Stage 2 | 127 | 23.7 | 235 | 19.3 |
|  | Stage 3 | 314 | 58.7 | 684 | 56.2 |
|  | Stage 4 | 33 | 6.2 | 130 | 10.7 |
| Year of ART initiation | |  |  |  |  |
|  | <2010 | NA | NA | 228 | 22.2 |
|  | 2010–2013 | 177 | 33.1 | 216 | 21.0 |
|  | 2014–2016 | 170 | 31.8 | 241 | 23.4 |
|  | 2017–2020 | 188 | 35.1 | 344 | 33.4 |
| TB PE-P | |  |  |  |  |
|  | No | 300 | 56.1 | 887 | 71.4 |
|  | Yes | 235 | 43.9 | 355 | 28.6 |
| Treatment regimen at enrollment | | |  |  |  |
|  | Nevirapine-based | 112 | 20.9 | 242 | 23.8 |
|  | Efavirenz-based | 423 | 79.1 | 775 | 76.2 |
| Opportunistic infection | |  |  |  |  |
|  | No | 350 | 65.4 | 1,007 | 81.1 |
|  | Yes | 185 | 34.6 | 235 | 18.9 |

Note: records with missing data are included in the excluded sample.

ART, antiretroviral therapy; WHO, World Health Organization; TB PE-P, tuberculosis post-exposure prophylaxis.